Zogenix Company Profile (NASDAQ:ZGNX)

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.85) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.03. The company earned $2.70 million during the quarter, compared to analyst estimates of $4.23 million. Zogenix had a negative return on equity of 57.74% and a negative net margin of 360.89%. Zogenix's quarterly revenue was down 70.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.42) EPS. View Zogenix's Earnings History.

3 brokers have issued 12-month price objectives for Zogenix's shares. Their predictions range from $17.00 to $28.00. On average, they anticipate Zogenix's stock price to reach $24.33 in the next year. View Analyst Ratings for Zogenix.

Here are some recent quotes from research analysts about Zogenix stock:

• 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (3/15/2017)
• 2. Aegis analysts commented, "adjunctive anti-epileptic therapy."Yang comments, "Study 1504 - a two cohort study to assess ZX008 as an adjunctive antiepileptic therapy. Designed as a multi-center study, 1504 is portioned into two cohorts that are a part of the phase III program for ZX008 in Dravet Syndrome. The first cohort assessed the pharmacokinetics and safety profile of ZX008 (fenfluramine hydrochloride), valproate, and clobazam when administered with stiripentol. In assessing these two aspects, cohort 1 served its primary purpose - identify the appropriate dosage of ZX008 to be used in the second cohort of the trial (0.5 mg/kg/day). Cohort 2 is designed as a double-blind, placebocontrolled trial randomizing 70 patients 1:1 (ZX008:placebo) after a 6 week baseline observation period. After a 3 week titration period, patients will receive either 0.5 mg/kg/day of ZX008 or equivalent placebo before being assessed at 12 weeks. The primary endpoint for cohort 2 is change from baseline in frequency of convulsive seizures, the same as study 1501 and 1502. All patients enrolled in the "stiripentol incomplete responder" trial will remain on their stable stiripentol drug regimen in addition to receiving either ZX008 or placebo." (2/14/2017)

Some companies that are related to Zogenix include PTC Therapeutics (PTCT), Editas Medicine (EDIT), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Cytokinetics, Incorporated (CYTK), Heska Corporation (HSKA), Anika Therapeutics (ANIK), China Cord Blood Corporation (CO), Aclaris Therapeutics (ACRS), Keryx Biopharmaceuticals (KERX), NeoGenomics (NEO), Depomed (DEPO), Novadaq Technologies (NVDQ), GenMark Diagnostics (GNMK), Mesoblast Limited (MESO), Paratek Pharmaceuticals (PRTK), Civitas Solutions (CIVI) and Sangamo BioSciences (SGMO).

Zogenix's management team includes the folowing people:

• Cam L. Garner, Independent Chairman of the Board
• Stephen J. Farr Ph.D., President, Chief Executive Officer, Director
• Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary
• Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer
• Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer
• Thierry J P Darcis, Executive Vice President and General Manager of Europe of Brabant Pharma Ltd.
• James B. Breitmeyer M.D., Ph.D., Director
• Roger L. Hawley, Director
• Erle T. Mast, Independent Director
• Mark C. Wiggins, Independent Director

Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (9.88%), Perceptive Advisors LLC (8.88%), FMR LLC (0.00%), Kennedy Capital Management Inc. (0.00%), Vanguard Group Inc. (0.00%) and Goldman Sachs Group Inc. (3.54%). Company insiders that own Zogenix stock include Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Zogenix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, City Financial Investment Co Ltd, Bank of America Corp DE, Wells Fargo & Company MN, Morgan Stanley, JPMorgan Chase & Co., TIAA CREF Investment Management LLC and ProShare Advisors LLC. View Insider Buying and Selling for Zogenix.

Zogenix's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Kennedy Capital Management Inc., Dimensional Fund Advisors LP, Sphera Funds Management LTD., Candriam Luxembourg S.C.A., Vanguard Group Inc., Ameriprise Financial Inc. and California Public Employees Retirement System. Company insiders that have bought Zogenix stock in the last two years include Renee P Tannenbaum and Roger Hawley. View Insider Buying and Selling for Zogenix.

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zogenix stock can currently be purchased for approximately $15.00.